title: [Clinical analysis of therapeutic effect of zoledronic acid combined with radiotherapy for metastatic bone cancer].
abstract: OBJECTIVE
  To evaluate the efficacy of zoledronic acid combined with local radiotherapy for limited metastatic bone cancer.
  
  
  METHODS
  Forty-five patients with limited bone metastatic cancers were randomly divided into two groups: 23 in the combination group who received intravenously administration of zoledronic acid and local radiotherapy, the other 22 in the radiotherapy alone group who underwent local radiotherapy only.
  
  
  RESULTS
  The response rate of pain relief was 91.3% in the combination group versus 86.4% in the radiotherapy alone group, without statistically significant difference between two groups (P > 0.05). However, the recalcification rate was significantly higher in the combination therapy group (52.2%) than that in radiotherapy alone group (22.7% P < 0.01), and the proportion of patients with new bone metastasis formation was significantly lower in the combination group (13.0%) than that in the radiotherapy alone group (40.9%, P < 0.05). The common side-effects were transient pyrexia and nausea.
  
  
  CONCLUSIONS
  Zoledronic acid combined with local radiotherapy is effective in relieving pain, improving bone recalcification and reducing the formation of new bone metastasis.
authors.affiliation: Department of Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430023, China. chenjin1118@hotmail.com
authors.forename: Jing
authors.initials: J
authors.lastname: Cheng
authors.forename: Jun
authors.initials: J
authors.lastname: Xue
authors.forename: Hong-Ge
authors.initials: HG
authors.lastname: Wu
authors.forename: Gang
authors.initials: G
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D001861:Bone Regeneration / Q000187:drug effects; D001943:Breast Neoplasms / Q000473:pathology; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000473:pathology; D010146:Pain / Q000209:etiology; D059408:Pain Management; D011878:Radiotherapy; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid